While the degree of disease modification of current treatments and the utility of NfL in clinical trials continue to be investigated, the field of ALS-therapy development would greatly benefit from the establishment of additional novel biomarkers of early or preclinical pathology. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.